Overview

Guselkumab Immunogenetics

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Janssen Biotech, Inc.